In the AHA/ACC Science Advisory, “Influenza Vaccination as Secondary Prevention for Cardiovascular Disease: A Science Advisory From the American Heart Association/American College of Cardiology,” which appeared in the October 3, 2006, issue (Circulation. 2006;114:1549–1553), the following items require correction:
In the third sentence of the Abstract (page 1549), “contraindicated” should be replaced by “not currently recommended,” to read: “Immunization with live, attenuated vaccine (administered intranasally) is not currently recommended for persons with cardiovascular conditions.”
In the last sentence of the first paragraph under “Influenza Illness and Influenza Vaccine” (page 1550), “antigenic shifts are more pronounced than usual” should be replaced by “a new influenza A virus emerges in humans through antigenic shift,” to read: “Pandemic influenza may occur when a new influenza A virus emerges in humans through antigenic shift.2”
In the third paragraph under “Influenza Illness and Influenza Vaccine” (page 1550), the last sentence, “It is important to note that individuals with CVD should not receive the live, attenuated influenza vaccine because it can cause influenza illness in this high-risk population,2” should be replaced by the following: “It is currently recommended that individuals with CVD not receive the live, attenuated influenza vaccine because it has not been approved for use in persons with CVD or other conditions that increase the risk of influenza-related complications.2”
In the Table (page 1552), “Flurix” should be spelled “Fluarix.” Also, in the first footnote, “is not recommended” should be replaced by “is not currently recommended,” to read: “*These are manufacturers of inactivated trivalent influenza vaccine. Live, attenuated intranasal influenza vaccine (FluMist; MedImmune) is not currently recommended for individuals with cardiovascular conditions.”
These errors have been corrected in the current online version of the article.